Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|||
| Income Statement [Abstract] | ||||||
| Net revenue | $ 1,446,066 | $ 2,350,386 | $ 4,569,146 | $ 7,154,429 | ||
| Operating expenses: | ||||||
| Direct costs and expenses | 942,211 | 1,440,158 | 3,326,673 | 4,421,309 | ||
| Research and development | 330,589 | 274,497 | 1,009,347 | 1,070,569 | ||
| Clinical development | 143,311 | 93,705 | 410,943 | 194,127 | ||
| Selling, general and administrative | 2,209,441 | 2,364,592 | 6,876,551 | 7,023,311 | ||
| Depreciation and amortization | 113,360 | 151,298 | 381,177 | 452,005 | ||
| Total operating expenses | 3,738,912 | 4,324,250 | 12,004,691 | 13,161,321 | ||
| Loss from operations | (2,292,846) | (1,973,864) | (7,435,545) | (6,006,892) | ||
| Other income (expense): | ||||||
| Interest income | 1,088 | 2,228 | 3,655 | 13,541 | ||
| Interest expense | (5,358) | (21,631) | (31,303) | (67,430) | ||
| Other income | 513 | 9,683 | 38,568 | 9,683 | ||
| Other expense | (3,839) | (14,697) | (496,524) | (10,186) | ||
| Change in fair value of warrants issued | (2,747,460) | (3,810,278) | ||||
| Total other income (expense), net | (2,755,056) | (24,417) | (4,295,882) | (54,392) | ||
| Net loss before provision for income tax expense | (5,047,902) | (1,998,281) | (11,731,427) | (6,061,284) | ||
| Provision for income tax expense | 3,182 | 2,559 | 40,861 | 11,650 | ||
| Net loss | $ (5,051,084) | $ (2,000,840) | $ (11,772,288) | $ (6,072,934) | ||
| Net loss per common share, basic | [1] | $ (4.74) | $ (4.84) | $ (7.55) | $ (16.22) | |
| Net loss per common share, diluted | [1] | $ (4.74) | $ (4.84) | $ (7.55) | $ (16.22) | |
| Weighted average common shares outstanding, basic | [1] | 1,066,350 | 412,936 | 804,604 | 374,445 | |
| Weighted average common shares outstanding, diluted | [1] | 1,066,350 | 412,936 | 804,604 | 374,445 | |
| ||||||
| X | ||||||||||
- Definition Change in fair value of warrants issued. No definition available.
|
| X | ||||||||||
- Definition Clinical development expense. No definition available.
|
| X | ||||||||||
- Definition Direct costs and expenses. No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|